This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Retain Edwards Lifesciences (EW) Now
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences' (EW) strong segmental performance and the growing demand for its RESILIA tissue valves.
Reasons Why You Should Invest in ResMed (RMD) Stock Now
by Zacks Equity Research
Investors are optimistic about ResMed's (RMD) robust mask and device sales and continued product innovations.
Tandem Diabetes (TNDM) New Launches Aid Growth Amid Cost Woes
by Zacks Equity Research
Tandem Diabetes (TNDM) witnesses strong customer retention, driven by the impressive positive response from the Control-IQ technology.
Bruker (BRKR) International Growth Strong Amid Competition
by Zacks Equity Research
Bruker (BRKR) Nano Group's microelectronics and semiconductor metrology tools continue to perform well with ongoing strength in bookings and backlog.
Here's Why Investors Should Retain Charles River (CRL) Now
by Zacks Equity Research
Investors are optimistic about Charles River's (CRL) strong segmental growth and notable collaborations.
ChemoCentryx's (CCXI) Tavneos Aids Growth, Overdependence a Woe
by Zacks Equity Research
ChemoCentryx (CCXI) has only one product approved for sale in its portfolio, Tavneos. Nevertheless, it is progressing well with the clinical development of its pipeline candidates.
Corcept (CORT) Thrives on Korlym Amid Overdependence Concerns
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug, Korlym, is making good progress. Other pipeline candidates are advancing as well. However, heavy dependence on Korlym for growth remains an overhang.
Exelixis (EXEL) Outperforms Industry in 1H22: What Lies Ahead?
by Zacks Equity Research
Exelixis (EXEL) outperforms the industry in the year so far on Cabometyx performance and pipeline progress.
AstraZeneca (AZN) to Buy TeneoTwo, Boost Hematology Pipeline
by Zacks Equity Research
AstraZeneca's (AZN) acquisition of TeneoTwo is set to add an early-stage T-cell engager to AZN's pipeline. The transaction is likely to close by third-quarter 2022.
Why Merck (MRK) Could Beat Earnings Estimates Again
by Zacks Equity Research
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Q3 Likely to Remain Volatile: Top 5 Picks to Stay Safe
by Nalak Das
We have narrowed our search to five large-cap, low-beta stocks with a solid dividend yield. These are: HSY, LMT, MRK, AEP and CPB.
Sanofi's (SNY) Studies on BTK Inhibitor Put on Hold by FDA
by Zacks Equity Research
Sanofi (SNY) pauses enrollment in late-stage studies evaluating its BTK inhibitor in multiple sclerosis and myasthenia gravis after the FDA places a partial clinical hold on these studies.
Pfizer (PFE) Seeks FDA Nod for Its Oral Antiviral COVID Pill
by Zacks Equity Research
Pfizer (PFE) submits NDA to the FDA seeking approval for using its oral antiviral COVID pill in vaccinated and unvaccinated patients at a high risk of developing severe COVID-19 complications.
Has Merck & Co. (MRK) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Merck (MRK) and Patterson Cos. (PDCO) have performed compared to their sector so far this year.
The Zacks Analyst Blog Highlights Sanofi, Merck, Novartis, Pfizer and J&J
by Zacks Equity Research
Sanofi, Merck, Novartis, Pfizer and J&J are part of Zacks top Analyst Blog.
Walgreens Boots (WBA) Q3 Earnings Top Estimates, Revenues Miss
by Zacks Equity Research
Walgreens Boots (WBA) reports better-than-expected Q3 earnings, with robust sales contributions from the International and Walgreens Health segments.
Pharma Stock Roundup: FDA Panel Backs Updated COVID Jabs, EU Nod for SNY, MRK Drugs
by Kinjel Shah
An FDA panel recommends updating COVID-19 booster shots. EU approvals for Sanofi's (SNY) two new drugs and expanded use of Merck's (MRK) Keytruda and Novartis' (NVS) Cosentyx.
Merck (MRK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $92.51, marking a +0.67% move from the previous day.
Top Analyst Reports for Meta Platforms, Eli Lilly & Home Depot
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (META), Eli Lilly and Company (LLY), and The Home Depot, Inc. (HD).
3 Reasons Why Merck (MRK) Is a Great Growth Stock
by Zacks Equity Research
Merck (MRK) possesses solid growth attributes, which could help it handily outperform the market.
Seagen (SGEN) Up More Than 20% in Past 3 Months: Here's Why
by Zacks Equity Research
Seagen (SGEN) is riding on the strong uptake of its marketed drugs that are approved for different cancer indications. Further label expansion of these drugs should boost the top line.
Merck (MRK) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
4 Reasons Why Investors Should Buy Merck (MRK) Stock Now
by Zacks Equity Research
Strong sales of key products like Keytruda and Gardasil, a significant contribution from Lagevrio and a solid pipeline are some key reasons to own Merck's (MRK) stock.
Sutro Biopharma (STRO) Up 50% on Cancer Treatment Collaboration
by Zacks Equity Research
Sutro Biopharma (STRO) inks a partnership and licensing deal with Astellas Pharma to discover and develop iADCs for cancer patients not responding to existing therapies.
AstraZeneca (AZN) Drugs Get CHMP Recommendation for Breast Cancer
by Zacks Equity Research
The EMA's Committee for Medicinal Products for Human Use recommends granting marketing approval to AstraZeneca's (AZN) cancer drugs, Enhertu and Lynparza, for treating certain patients with breast cancer.